litlas
ログインアカウント作成

Mario E. Lacouture

2001–2025 年に発表

144
論文数
23,682
被引用数
88
h 指数
141
i10 指数

被引用数

Mario E. Lacouture の年別被引用数2002 年: 被引用 6 件2004 年: 被引用 1 件2005 年: 被引用 3 件2006 年: 被引用 6 件2007 年: 被引用 15 件2008 年: 被引用 21 件2009 年: 被引用 66 件2010 年: 被引用 72 件2011 年: 被引用 73 件2012 年: 被引用 67 件2013 年: 被引用 95 件2014 年: 被引用 87 件2015 年: 被引用 118 件2016 年: 被引用 189 件2017 年: 被引用 230 件2018 年: 被引用 253 件2019 年: 被引用 931 件2020 年: 被引用 1,118 件2021 年: 被引用 1,075 件2022 年: 被引用 805 件2023 年: 被引用 588 件2024 年: 被引用 1,098 件2025 年: 被引用 505 件2026 年: 被引用 6 件2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,462 件、この内訳の 26.4%中国: 引用元論文 1,067 件、この内訳の 11.4%イタリア: 引用元論文 627 件、この内訳の 6.7%フランス: 引用元論文 490 件、この内訳の 5.3%ドイツ: 引用元論文 452 件、この内訳の 4.8%イギリス: 引用元論文 447 件、この内訳の 4.8%日本: 引用元論文 329 件、この内訳の 3.5%スペイン: 引用元論文 298 件、この内訳の 3.2%カナダ: 引用元論文 289 件、この内訳の 3.1%オーストラリア: 引用元論文 267 件、この内訳の 2.9%オランダ: 引用元論文 219 件、この内訳の 2.4%スイス: 引用元論文 216 件、この内訳の 2.3%
0%26.4%その他 23.2%

機関

分野

  • Medicine76.4%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology3.9%
  • Engineering1%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Neuroscience0.4%
  • その他1.9%

トピック

  • Cancer Immunotherapy and Biomarkers12%
  • Colorectal Cancer Treatments and Studies4.3%
  • CAR-T cell therapy research3.2%
  • Melanoma and MAPK Pathways2.7%
  • Lung Cancer Treatments and Mutations2.7%
  • Immunotherapy and Immune Responses2.4%
  • その他72.7%

共著者

全論文

検索で開く
  1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    著者: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 被引用: 826

  2. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    著者: on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, Cynthia F. Brogdon, Ramona Dadu, Lamya Hamad, Sungjun Kim, Mario E. Lacouture, Nicole R. LeBoeuf, Dan Lenihan, C.D. Onofrei, Vickie R. Shannon, Rajeev Sharma, Ann W. Silk, Dimitra Skondra, María E. Suarez‐Almazor, Yinghong Wang, Kathleen E. Wiley, Howard L. Kaufman, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2017 被引用: 1,984

  3. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    著者: Jarushka Naidoo, David B. Page, Bob T. Li, Louise C. Connell, Katja Schindler, Mario E. Lacouture, Michael A. Postow, Jedd D. Wolchok - Annals of Oncology 2015 被引用: 1,463

  4. Immune checkpoint inhibitor–related dermatologic adverse events

    著者: Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, Jennifer Wu, Donald Y.M. Leung, Andrea P. Moy, Jeffrey A. Kern, Mario E. Lacouture - Journal of the American Academy of Dermatology 2020 被引用: 462

  5. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    著者: Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki L. Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang‐Gillam, Mario Sznol, Keith T. Flaherty, Elizabeth I. Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary DeCrescenzo, Caroline M. Emery, Anna Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li - Cancer Discovery 2017 被引用: 418

  6. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

    著者: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2019 被引用: 560

  7. Efficacy of MEK inhibition in patients with histiocytic neoplasms

    著者: Eli L. Diamond, Benjamin H. Durham, Gary A. Ulaner, Esther Drill, Justin J. Buthorn, Michelle Ki, Lillian Bitner, Hanna Cho, Robert J. Young, Jasmine H. Francis, Raajit K. Rampal, Mario E. Lacouture, Lynn A. Brody, Neval Özkaya, Ahmet Doǧan, Neal Rosen, Alexia Iasonos, Omar Abdel‐Wahab, David M. Hyman - Nature 2019 被引用: 384

  8. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

    著者: Mario E. Lacouture, V. Sibaud - American Journal of Clinical Dermatology 2018 被引用: 355

  9. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

    著者: Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David H. Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan‐Birsoy, Gary A. Ulaner, Michael F. Walsh, Mariko Yabe, Kseniya Petrova‐Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa‐María López, Jaume Mora, Julien Haroche, Jean‐François Emile, Olivier Decaux, Frédéric Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel‐Wahab - Nature Medicine 2019 被引用: 228

  10. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

    著者: Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Ai Ni, Mario E. Lacouture, Maya Gambarin‐Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann - Cancer Immunology Research 2018 被引用: 332

  11. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

    著者: Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart, Jean‐Yves Blay, Igor Puzanov, Ian Chau, Noopur Raje, Jürgen Wolf, Joseph P. Erinjeri, Jean Torrisi, Mario E. Lacouture, Elena Élez, Ferran Martínez-Valle, Benjamin H. Durham, Maria E. Arcila, Gary A. Ulaner, Omar Abdel‐Wahab, Bethany Pitcher, Martina Makrutzki, Todd Riehl, José Baselga, David M. Hyman - JAMA Oncology 2017 被引用: 405

  12. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

    著者: Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg, Peter H. O’Donnell - The Oncologist 2022 被引用: 141

  13. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    著者: Eli L. Diamond, Benjamin H. Durham, Julien Haroche, Zhan Yao, Jing Ma, Sameer A. Parikh, Zhaoming Wang, John Choi, Eun Hee Kim, Fleur Cohen‐Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean‐Baptiste Micol, Patrick Campbell, Michael P. Walsh, Brooke E. Sylvester, Igor Dolgalev, Olga Aminova, Adriana Heguy, Paul Zappile, Joy Nakitandwe, Chezi Ganzel, James Dalton, David W. Ellison, Juvianee Estrada‐Veras, Mario E. Lacouture, William A. Gahl, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Samuel Briggs, Omotayo Fasan, Jared Block, Sébastien Héritier, Jean Donadieu, David B. Solit, David M. Hyman, José Baselga, Filip Jankú, Barry S. Taylor, Christopher Y. Park, Zahir Amoura, Ahmet Doǧan, Jean‐François Emile, Neal Rosen, Tanja A. Grüber, Omar Abdel‐Wahab - Cancer Discovery 2015 被引用: 533

  14. Treatment Outcomes of Immune-Related Cutaneous Adverse Events

    著者: Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann, Michael A. Postow, Naiyer A. Rizvi, Azael Freites‐Martínez, Donald Chan, Stephen W. Dusza, Robert J. Motzer, Jonathan E. Rosenberg, Margaret K. Callahan, Paul B. Chapman, Larisa J. Geskin, Adriana T. Lopez, Vanessa A. Reed, Gabriella Fabbrocini, Maria Carmela Annunziata, Oluwaseun Kukoyi, Aliyah Pabani, Chih-Hsun Yang, Wen‐Hung Chung, Alina Markova, Mario E. Lacouture - Journal of Clinical Oncology 2019 被引用: 235

  15. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

    著者: Viswanath Reddy Belum, Benjamin Benhuri, Michael A. Postow, Matthew D. Hellmann, Alexander M. Lesokhin, Neil H. Segal, Robert J. Motzer, Shenhong Wu, Klaus J. Busam, Jedd D. Wolchok, Mario E. Lacouture - European Journal of Cancer 2016 被引用: 415

  16. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

    著者: Heather L. McArthur, Adi Diab, David B. Page, Jianda Yuan, Stephen B. Solomon, Virgilio Sacchini, Christopher Comstock, Jeremy C. Durack, Majid Maybody, Janice S. Sung, Arielle A. Ginsberg, Phillip Wong, Afşar Barlas, Zhiwan Dong, Chunjun Zhao, Brian Blum, Sujata Patil, Deirdre Neville, Elizabeth Comen, Elizabeth A. Morris, Alan Kotin, Edi Brogi, Yuetao Wen, Monica Morrow, Mario E. Lacouture, Padmanee Sharma, James P. Allison, Clifford A. Hudis, Jedd D. Wolchok, Larry Norton - Clinical Cancer Research 2016 被引用: 224

  17. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

    著者: Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee Cowan, Elizabeth Comen, Andy Singh, Anne M. Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis‐Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty - Nature Cancer 2020 被引用: 162

  18. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

    著者: Jia Luo, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey A. Kern, Donald Y.M. Leung, Mario E. Lacouture, Mark G. Kris, Maya Gambarin, Bianca Santomasso, David M. Faleck, Matthew D. Hellmann - Journal of Thoracic Oncology 2021 被引用: 109

  19. European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    著者: Zoé Apalla, Vasiliki Nikolaou, Davide Fattore, Gabriella Fabbrocini, Azael Freites‐Martínez, Pietro Sollena, Mario E. Lacouture, Lukas Kraehenbuehl, Alexander Stratigos, Ketty Peris, Elizabeth Lazaridou, Bertrand Richert, Émmanuelle Vigarios, Julia Riganti, Barouyr Baroudjian, Angela Filoni, Roni P. Dodiuk‐Gad, Célèste Lebbé, V. Sibaud - Journal of the European Academy of Dermatology and Venereology 2021 被引用: 99

  20. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

    著者: Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis Dockter, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeffrey P. Meyers, Rodwige J. Desnoyers, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Jeffrey A. Sloan, Mario E. Lacouture, Heinz‐Josef Lenz, Axel Grothey - The Lancet Oncology 2019 被引用: 284

  21. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

    著者: Mario E. Lacouture, John C. Morris, Donald P. Lawrence, Antoinette R. Tan, Thomas Olencki, Geoffrey I. Shapiro, Bruce J. Dezube, Jay A. Berzofsky, Frank J. Hsu, Joan Guitart - Cancer Immunology Immunotherapy 2015 被引用: 150

  22. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

    著者: Francisco Sánchez-Vega, Jaclyn F. Hechtman, Pau Castel, Geoffrey Y. Ku, Yaelle Tuvy, Helen Won, Christopher J. Fong, Nancy Bouvier, Gouri J. Nanjangud, Joanne Soong, Efsevia Vakiani, Mark Schattner, David P. Kelsen, Robert A. Lefkowitz, Karen T. Brown, Mario E. Lacouture, Marinela Capanu, Marissa S. Mattar, Besnik Qeriqi, Fabiola Cecchi, Yuan Tian, Todd Hembrough, Rebecca J. Nagy, Richard B. Lanman, Steven M. Larson, Neeta Pandit‐Taskar, Heiko Schöder, Christine A. Iacobuzio–Donahue, David H. Ilson, Wolfgang Weber, Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y. Janjigian - Cancer Discovery 2018 被引用: 147

  23. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

    著者: Samuel Cytryn, Ryan H. Moy, Darren Cowzer, Ronak Shah, Joanne F. Chou, Smita S. Joshi, Geoffrey Y. Ku, Steven B. Maron, Avni M. Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, M. A. Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Mark Schattner, Marc Simmons, Mario E. Lacouture, Viktoriya Paroder, Laura H. Tang, Jinru Shia, David H. Ilson, David B. Solit, Michael F. Berger, Yelena Y. Janjigian - The Lancet Oncology 2023 被引用: 45

  24. Mechanisms of cutaneous toxicities to EGFR inhibitors

    著者: Mario E. Lacouture - Nature reviews. Cancer 2006 被引用: 776